Edition:
India

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

36.26USD
16 Feb 2018
Change (% chg)

$0.55 (+1.54%)
Prev Close
$35.71
Open
$35.76
Day's High
$36.65
Day's Low
$35.76
Volume
9,141,375
Avg. Vol
6,113,762
52-wk High
$39.43
52-wk Low
$31.67

Latest Key Developments (Source: Significant Developments)

Pfizer Q4 Worldwide Total Lyrica Rev $‍​1,130 Mln
Tuesday, 30 Jan 2018 

Jan 30 (Reuters) - Pfizer Inc ::PFIZER INC QTRLY WORLDWIDE TOTAL LYRICA REVENUE $‍​1,130 MILLION VERSUS $1,057 MILLION.PFIZER INC QTRLY WORLDWIDE PREVNAR FAMILY REVENUE $‍​1,533 MILLION VERSUS $1,416 MILLION.PFIZER INC QTRLY WORLDWIDE IBRANCE REVENUE $716 MILLION VERSUS $643 MILLION.PFIZER INC QTRLY WORLDWIDE LIPITOR REVENUE $574 MILLION VERSUS $464 MILLION.  Full Article

Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan/Mabthera
Wednesday, 24 Jan 2018 

Jan 24 (Reuters) - Pfizer Inc ::PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FOR POTENTIAL BIOSIMILAR TO RITUXAN®/MABTHERA®.PFIZER INC - PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FOR POTENTIAL BIOSIMILAR TO RITUXAN(®)/MABTHERA(®).PFIZER INC - RESULTS FROM COMPARATIVE REFLECTIONS B3281006 STUDY DEMONSTRATE EQUIVALENCE IN PATIENTS WITH INDOLENT FOLLICULAR LYMPHOMA.PFIZER INC - REFLECTIONS B3281006, A COMPARATIVE SAFETY AND EFFICACY STUDY OF PF-05280586 VERSUS MABTHERA(®) (RITUXIMAB-EU), MET ITS PRIMARY ENDPOINT.PFIZER - TRIAL DEMONSTRATED EQUIVALENCE IN OVERALL RESPONSE RATE FOR FIRST-LINE TREATMENT OF PATIENTS WITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA.  Full Article

Kite Announces Clinical Collaboration With Pfizer
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Gilead Sciences Inc ::KITE ANNOUNCES CLINICAL COLLABORATION TO EVALUATE INVESTIGATIONAL COMBINATION OF YESCARTA™ (AXICABTAGENE CILOLEUCEL) AND PFIZER’S UTOMILUMAB IN LARGE B-CELL LYMPHOMA.GILEAD SCIENCES INC - KITE ENTERED INTO A CLINICAL TRIAL COLLABORATION WITH PFIZER, INC.GILEAD SCIENCES INC - MULTI-CENTER PHASE 1/2 STUDY SPONSORED BY KITE IS EXPECTED TO BEGIN IN 2018.GILEAD SCIENCES INC - RESULTS OF STUDY WILL BE USED TO EVALUATE OPTIONS FOR FURTHER DEVELOPMENT OF THE COMBINATION, OR SIMILAR COMBINATIONS.  Full Article

Foundation Medicine, Pfizer Announce Partnership To Develop Companion Diagnostics For Pfizer’S Oncology Portfolio
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Foundation Medicine Inc ::FOUNDATION MEDICINE AND PFIZER ANNOUNCE BROAD PARTNERSHIP TO DEVELOP COMPANION DIAGNOSTICS FOR PFIZER’S ONCOLOGY PORTFOLIO.FOUNDATION MEDICINE - PARTNERSHIP FOCUSES ON DEVELOPMENT, REGULATORY SUPPORT AND COMMERCIALIZATION OF COMPANION DIAGNOSTICS.FOUNDATION MEDICINE - CENTERS FOR MEDICARE & MEDICAID SERVICES ISSUED PRELIMINARY NATIONAL COVERAGE DETERMINATION FOR FOUNDATIONONE CDX.FOUNDATION MEDICINE INC - FINAL POLICY FOR FOUNDATIONONE CDX IS EXPECTED TO ISSUE DURING Q1 OF 2018.  Full Article

Novartis poaches Pfizer oncology head Elizabeth Barrett
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Novartis says::Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc. <<>>, has been appointed CEO Novartis Oncology and a member of the Executive Committee of Novartis, effective February 1, 2018.Barrett succeeds Bruno Strigini who decided to retire from Novartis for personal reasons.  Full Article

Pfizer Announces Expiration, Results Of Tender Offer For Its 5.750 pct
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Pfizer Inc ::PFIZER INC. ANNOUNCES EXPIRATION AND RESULTS OF ITS TENDER OFFER FOR ITS 5.750 PER CENT. NOTES DUE 2021 AND RELATED SOLICITATION OF CONSENTS.PFIZER -EXPIRATION, RESULTS OF PREVIOUSLY ANNOUNCED OFFER TO PURCHASE FOR CASH ANY AND ALL OF ITS OUTSTANDING EUR 2 BILLION 5.750 PER CENT. NOTES DUE 2021.PFIZER INC. ANNOUNCES EXPIRATION AND RESULTS OF ITS TENDER OFFER FOR ITS 5.750 PER CENT. NOTES DUE 2021 AND RELATED SOLICITATION OF CONSENTS.  Full Article

Jacobs Appointed As EPCM Contractor For New Gene Therapy Manufacturing Facility
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Jacobs Engineering Group Inc ::JACOBS APPOINTED AS EPCM CONTRACTOR FOR NEW GENE THERAPY MANUFACTURING FACILITY.JACOBS ENGINEERING GROUP - ‍RECEIVED ENGINEERING, PROCUREMENT AND CONSTRUCTION MANAGEMENT CONTRACT FROM PFIZER INC.​.JACOBS ENGINEERING GROUP - RECEIVED THE CONTRACT FOR NEW GENE THERAPY MANUFACTURING FACILITY LOCATED AT CO'S MANUFACTURING SITE IN NORTH CAROLINA.JACOBS ENGINEERING - ‍UNDER TERMS OF CONTRACT, CO TO PERFORM ALL REQUIRED SERVICES TO DESIGN, BUILD, QUALIFY NEW GENE THERAPY MANUFACTURING FACILITY​.  Full Article

Arvinas announces research collaboration and license agreement with Pfizer Inc
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Arvinas LLC::ARVINAS ANNOUNCES RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH PFIZER INC. FOR THE DISCOVERY AND DEVELOPMENT OF PROTEIN DEGRADATION DRUG CANDIDATES.ANNOUNCED A RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH PFIZER INC​.ARVINAS SAYS MAY RECEIVE UP TO $830 MILLION IN UPFRONT AND POTENTIAL DEVELOPMENT AND COMMERCIALIZATION MILESTONE PAYMENTS UPON ACHIEVEMENT OF SPECIFIED MILESTONES​.‍CO MAY BE ENTITLED TO RECEIVE TIERED ROYALTIES BASED ON GLOBAL PRODUCT SALES ON ANY PRODUCTS THAT MAY RESULT FROM COLLABORATION​.  Full Article

Sangamo And Pfizer Announce Collaboration For Development Of Zinc Finger Protein Gene Therapy For Als
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Pfizer Inc ::SANGAMO AND PFIZER ANNOUNCE COLLABORATION FOR DEVELOPMENT OF ZINC FINGER PROTEIN GENE THERAPY FOR ALS.SANGAMO THERAPEUTICS​ - CO, ‍PFIZER ANNOUNCED COLLABORATION FOR DEVELOPMENT OF ZINC FINGER PROTEIN GENE THERAPY FOR ALS.SANGAMO THERAPEUTICS INC - UNDER TERMS OF COLLABORATION AGREEMENT, SANGAMO WILL RECEIVE A $12 MILLION UPFRONT PAYMENT FROM PFIZER.SANGAMO THERAPEUTICS INC - UNDER AGREEMENT, CO ‍WILL BE RESPONSIBLE FOR DEVELOPMENT OF ZFP-TF CANDIDATES​.SANGAMO - UNDER TERMS ELIGIBLE TO RECEIVE POTENTIAL DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS UP TO $150 MILLION, TIERED ROYALTIES ON NET SALES.SANGAMO - UNDER DEAL,‍PFIZER OPERATIONALLY,FINANCIALLY RESPONSIBLE FOR RESEARCH,DEVELOPMENT,COMMERCIALIZATION FOR C9ORF72 ZFP-TF,RESULTING PRODUCTS.  Full Article

Pfizer Announces Breakthrough Therapy Designation For Avelumab In Combination With Inlyta
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Pfizer Inc ::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR AVELUMAB IN COMBINATION WITH INLYTA® IN ADVANCED RENAL CELL CARCINOMA.PFIZER - BREAKTHROUGH THERAPY DESIGNATION IS BASED ON PRELIMINARY EVALUATION OF CLINICAL DATA FROM JAVELIN RENAL 100 STUDY.  Full Article

Photo

Shares of Apricus tank after FDA declines to OK erectile dysfunction cream

The U.S. Food and Drug Administration on Friday declined to approve Apricus Biosciences Inc's Vitaros, a cream to treat erectile dysfunction, for the second time in a decade, sending the company's shares down more than 70 percent before the opening bell.